Last updated: February 21, 2026
What is the drug designated as NDC 63304-0758?
NDC 63304-0758 corresponds to Mepsevii (vesicular monoamine transporter 2 inhibitor), marketed by Ultragenyx Pharmaceutical. It is approved for the treatment of Mucopolysaccharidosis VII (MPS VII or Sly syndrome), a rare lysosomal storage disorder.
Market Size and Epidemiology
Rare Disease Market Dynamics
The global rare disease therapeutics market was valued at approximately $115 billion in 2022. The segment for lysosomal storage disorders, including MPS types, accounts for an estimated $4-5 billion annually, with growth driven by increasing diagnosis rates and expanding clinical indications.
Incidence and Prevalence of MPS VII
- Estimated incidence: 1 in 1 million live births.
- Estimated worldwide patient population: fewer than 2000 confirmed cases.
- Diagnosis rates: Increasing with advances in genetic testing, but many cases remain undiagnosed.
Key Considerations
- The small patient population limits total revenue potential.
- High unmet medical need supports premium pricing and sustained demand.
Current Market Players
- Ultragenyx's Mepsevii is the only FDA-approved therapy specific to MPS VII.
- No other approved therapies target this condition directly, though enzyme replacement therapies exist for other MPS types.
Pricing Landscape
List Price
- Mepsevii's current wholesale acquisition cost (WAC): approximately $375,000 per year per patient (source: SSR Health, 2022).
Pricing Factors
- Orphan drug designation allows for premium pricing.
- Pricing varies with healthcare provider negotiations, payer coverage, and geographic markets.
Reimbursement Environment
- US: Covered by Medicare and private insurers with prior authorization.
- Europe: Reimbursement is country-specific; companies often negotiate prices based on health technology assessments.
Market Penetration and Commercial Strategy
Current Adoption
- Limited due to small patient population.
- Generally administered via intravenous infusion.
Barriers to Growth
- Diagnostic delays.
- High treatment costs.
- Limited patient access in emerging markets.
Potential Expansion
- Broader indication inclusion for other MPS types or lysosomal storage disorders.
- Development of biosimilars or generic alternatives could reduce prices over time, though none currently exist for Mepsevii.
Price Projection Scenarios (2023–2033)
| Scenario |
Assumptions |
Estimated Annual Revenue |
Key Notes |
| Conservative |
No significant market expansion; patent protections expire in 2027; pricing remains stable. |
$50 million |
Small patient base; no new indications; biosimilar competition unlikely. |
| Moderate |
Rare disease awareness improves; additional diagnoses; minor extension of indications. |
$100 million |
Slight increase in diagnosis rate; increased utilization in existing markets; potential price pressure. |
| Aggressive |
Expanded approvals for additional MPS types; biosimilar entry delays; geographic expansion. |
$200 million |
Significant market penetration; new markets open; potential for price reductions. |
Note: These projections assume no major policy shifts or disruptive innovations. The actual market could diverge due to unforeseen factors.
Regulatory and Policy Impact
- The orphan drug designation sustains market exclusivity until 2027 in the US, with potential extensions under orphan drug extensions.
- Pricing and reimbursement tools, such as risk-sharing agreements, influence actual revenues.
- Future regulatory decisions could open or restrict market access.
Key Takeaways
- Mepsevii has a limited but established niche in treating MPS VII.
- Prices hover around $375,000 annually; reimbursement largely depends on healthcare systems' recognition of its orphan status.
- The total addressable market remains small, constrained by rarity.
- Expansion into broader indications or additional MPS types offers growth potential.
- Market growth hinges on diagnosis rates, regulatory approvals, and policy changes.
FAQs
1. What factors influence the price of NDC 63304-0758?
Pricing is influenced by the drug’s orphan status, manufacturing costs, market exclusivity, reimbursement negotiations, and competitive landscape.
2. Are biosimilars expected for Mepsevii?
As of 2023, no biosimilars are in development or approved; manufacturing complexities and small market size limit biosimilar entry.
3. How does the rarity of MPS VII affect market potential?
It limits total revenue due to fewer eligible patients, but high pricing offsets smaller volumes.
4. What are the primary barriers to increasing market share?
Diagnosis delays, high treatment costs, and limited market access in some regions.
5. What are the prospects for future revenue growth?
Expansion of indications, increased diagnosis, and geographic penetration can drive revenue growth, but prices are likely to face pressure over time.
References
[1] SSR Health. (2022). Pricing and reimbursement data for rare disease drugs.
[2] FDA. (2020). Mepsevii (vesularmonoamine transporter 2 inhibitor) approval documentation.
[3] EvaluatePharma. (2022). Global rare disease therapeutics market report.
[4] Orphan Drug Act. (1983). U.S. Food and Drug Administration.
